RNAi

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines
Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines
Stat
Alnylam
rare disease
Patisiran
familial amyloid polyneuropathy
RNAi
Flag link:
Alnylam review turns up no clear answers on revusiran deaths
Alnylam review turns up no clear answers on revusiran deaths
BioPharma Dive
Alnylam
revusiran
RNAi
Flag link:
EuroBiotech Report: Brexit, BioNTech success, GlaxoSmithKline inks AI deal, Silence takes Alnylam to court and Shire makes cuts
EuroBiotech Report: Brexit, BioNTech success, GlaxoSmithKline inks AI deal, Silence takes Alnylam to court and Shire makes cuts
Fierce Biotech
Europe
biotech
Brexit
BioNTech
GSK
artificial intelligence
Sanofi
Exscientia
Silence Therapeutics
RNAi
Flag link:
Alnylam lines up Phase 3 for another RNAi drug
Alnylam lines up Phase 3 for another RNAi drug
BioPharma Dive
Alnylam
RNAi
givosiran
acute hepatic porphyrias
Flag link:
Alnylam shares crater after deaths force investigators to scrap PhIII RNAi drug
Alnylam shares crater after deaths force investigators to scrap PhIII RNAi drug
Endpoints
Alnylam
RNAi
clinical trials
Flag link:
Could Alnylam Pharmaceuticals Change Medicine as We Know It?
Could Alnylam Pharmaceuticals Change Medicine as We Know It?
Motley Fool
Alnylam
RNAi
Flag link:
Sanofi steps deeper into RNAi work, opts in on Alnylam hemophilia drug
Sanofi steps deeper into RNAi work, opts in on Alnylam hemophilia drug
Fierce Biotech
Sanofi
RNAi
Alnylam
ALN-AT3
Genzyme Sanofi
hemophilia
Flag link:
Tekmira's Ebola drug comes up short in Phase II
Tekmira's Ebola drug comes up short in Phase II
Fierce Biotech
Tekmira
ebola virus
TKM-EBOLA
RNAi
Flag link:
Alnylam's star RNAi drug keeps the pace on the way to Phase III
Alnylam's star RNAi drug keeps the pace on the way to Phase III
Fierce Biotech
Alnylam
RNAi
Patisiran
ATTR
Flag link:
Silence Therapeutics raises $58 million to advance R&D
Silence Therapeutics raises $58 million to advance R&D
BioPharma Dive
Silence Therapeutics
RNAi
R&D
Flag link:
Novartis sells its RNAi cast-offs from Alnylam in $35M fire sale to Arrowhead
Novartis sells its RNAi cast-offs from Alnylam in $35M fire sale to Arrowhead
Fierce Biotech
Novartis
Alnylam
RNAi
Arrowhead Research
Flag link:
Alnylam reports results from Phase 2 revusiran trial
Alnylam reports results from Phase 2 revusiran trial
Seeking Alpha
Alnylam
revusiran
TTR cardiac amyloidosis
RNAi
Flag link:
Study Suggests RNAi Drug Has Potential in Ebola Treatment
Study Suggests RNAi Drug Has Potential in Ebola Treatment
WSJ Pharmalot
ebola virus
Tekmira Pharmaceuticals
RNAi
NP-718m-LNP
Flag link:
5 Huge Biotech Catalysts Right Around the Corner for Top Stocks
5 Huge Biotech Catalysts Right Around the Corner for Top Stocks
24/7 Wall St
Arrowhead Research
Gilead Sciences
Intercept Pharmaceuticals
Amgen
Vertex Pharmaceuticals
RNAi
Kyprolis
VX-661
Sovaldi
Kalydeco
Flag link:
Is This the Crown Jewel of the ISIS Pipeline?
Is This the Crown Jewel of the ISIS Pipeline?
Motley Fool
Isis Pharmaceuticals
RNAi
ISIS-APOCIIIRx
Flag link:
Alnylam Strikes Back: Comments From CEO John Maraganore
Alnylam Strikes Back: Comments From CEO John Maraganore
Forbes
Pharma CEOs
John Maraganore
Alnylam
RNAi
Flag link:
Big Pharma's Turn On RNAi Shows That New Technologies Don't Guarantee R&D Success
Big Pharma's Turn On RNAi Shows That New Technologies Don't Guarantee R&D Success
Forbes
Big Pharma
RNAi
Novartis
Alnylam
Flag link:
Alnylam slips after Novartis reportedly cuts back RNAi development
Alnylam slips after Novartis reportedly cuts back RNAi development
The Fly on the Wall
Novartis
Alnylan
RNAi
Flag link:
Arrowhead: A Functional Cure For The Hepatitis B Virus
Arrowhead: A Functional Cure For The Hepatitis B Virus
Seeking Alpha
Arrowhead Research
hepatitis B
RNAi
Flag link:
Rise of Alnylam, ISIS Gives RNA Therapeutics Value
Rise of Alnylam, ISIS Gives RNA Therapeutics Value
Wall St Cheat Sheet
Alnylam
Isis Pharmaceuticals
RNAi
Flag link: